公开(公告)号：US20040242613A1

公开(公告)日：2004-12-02

申请号：US10766079

申请日：2004-01-27

申请人： Boehringer Ingelheim Pharmaceuticals, Inc. ,  Boehringer Ingelheim Pharma GmbH & Co. KG

发明人： Mario G. Cardozo ,  Derek Cogan ,  Charles Lawrence Cywin ,  Georg Dahmann ,  Darren DiSalvo ,  John David Ginn ,  Anthony S. Prokopowicz III ,  Denice M. Spero ,  Erick Young

IPC分类号： A61K031/506 ,  A61K031/505

CPC分类号： C07D239/48 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04 ,  H01L51/0089

摘要： Disclosed are novel compounds of formula (I): 1 wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

摘要翻译： 公开了式（I）的新化合物：其中R 1，R 2和R 3如本文所定义，其可用作PKC-θ的抑制剂，因此可用于治疗通过该活性介导或维持的多种疾病和病症 的PKC-θ，包括免疫学障碍和II型糖尿病。 本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和病症的方法，制备这些化合物的方法和可用于这些方法的中间体。